MEDP vs VRTX
Medpace vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | MEDP | VRTX |
|---|
| AI Score |
67
|
67
|
| Price |
$590.35
|
$496.21
|
| P/E Ratio |
33.97×
|
28.64×
|
| ROE |
98.3%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.8%
|
86.0%
|
| Debt / Equity |
0.28×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
64.4
|
66.6
|
| Beta |
1.151
|
0.292
|
| Expected Upside |
+5.5%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for MEDP versus VRTX.
The committee scores are tied.
MEDP and VRTX both score 67/100.
MEDP Committee View
80% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is bollinger bandwidth of 19.8% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 19.8% signals elevated volatility — Risk
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical